Hey, pharma: Data's more than a 'defense mechanism,' ad executive says

Question mark on zeroes and ones background
Data is a powerful tool for pharma marketers, but one ad agency data chief says they could be more effective by using it earlier and more strategically. (Getty Images Plus)

Data is here to stay in pharma marketing. However, while most pharma companies have begun to use data to make marketing decisions, one healthcare agency data veteran sees a recurring problem in the way that data is typically utilized.

Pharma marketers too often only use data after the fact, said Kevin Troyanos, senior VP of analytics at Saatchi & Saatchi Wellness. While post-campaign ROI analysis is important to find out what worked and what didn’t for the next effort, it can also lead to confirmation bias.

That’s when data is used to validate the HiPPO—Highest Paid Person’s Opinion—a term coined by a Google digital marketing executive. True data-driven companies use information dynamically to inform decisions, identify what works and what doesn’t work and to make changes on the fly, Troyanos said.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

“Pharma typically puts a lot of research into one tactic, one channel or one creative and are almost locked in to it. What happens then is that teams are leveraging data in a defensive way, essentially using it to say that the decision they made was the right one and this is why,” he said. “Pharma needs to begin to use data as a driver, not as a defense mechanism.”

RELATED: Will Facebook’s data-scraping woes bleed into healthcare and pharma?

Troyanos advocates moving data earlier into the process and adopting a more “fearless” attitude. Accept that some decisions won’t work, tinker with many different approaches and learn from mistakes.

Another way pharma and healthcare companies can use data more effectively is to use it in a more timely fashion. Instead of running ROI months after a campaign ends, use collected data during the campaign to make midstream tweaks to media or creative plans. As he noted, that’s standard operating procedure in marketing in other industries, but pharma companies are mostly still working toward that goal.

RELATED: Social listening data is good, but it's better when combined with offline insights: agency

And don’t forget predictive analytics and machine learning, Troyanos said. Instead of just using data to inform a creative execution or media plan, pharma can use sophisticated technology to predict, for instance, which specific doctors are likely to be earlier adopters of a new drug and spend media dollars accordingly.

“The sooner brands move from using data as a means to justify past actions to using data as a mechanism of organizational transformation, the sooner they will experience the benefits of truly data-driven decision-making,” he said.

Suggested Articles

Bayer Chairman Werner Baumann could face a vote a no confidence from its top investor, BlackRock, Reuters reported.

When Sanofi inked a massive lease in Cambridge Crossing last year, the drugmaker found itself in prime position for another real estate deal.

Amid China's tighter grip on antibiotics use, Lilly sold Chinese rights to two legacy antibiotics and a manufacturing facility to China's Eddingpharm.